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25, Number 8, August 2018Ophthalmology Volume 1Re: Gurwin et al.: A randomized
controlled study of art observation
training to improve medical
student ophthalmology skills
(Ophthalmology. 2018;125:8e14)TO THE EDITOR: During dinner recently, we discussed the article by
Gurwin et al1 on art observation training to improve medical
student ophthalmology skills at the University of Pennsylvania, as
well as the accompanying editorial by Gladwell and Epstein.2
One of us (R.M.J.) remembered learning about similar training
that was conceived of, implemented, and analyzed, 2 decades ago
by Dr Irwin Braverman (R.M.J.’s medical school dermatology
mentor), now Emeritus Professor of Dermatology at Yale Medical
School. This work is referenced, but not described, by Gurwin
et al.1 We think that your readership would enjoy learning a little
more about this earlier original work.
In the Yale study, published in the Journal of the American
Medical Association, first-year medical students first were given
3 minutes to describe in writing the salient attributes of photographs
of patients with medical disorders, and the quality of their de-
scriptions was graded in a masked, standardized fashion.3 They
were then randomly assigned to a control group (n ¼ 35) that
attended clinical tutorial sessions in which they were taught
history taking and physical examination by a physician preceptor,
and the intervention group. The intervention group attended a
program at the Yale Center for British Art. Each student studied
a preselected painting for 10 minutes and described it to a group
of 4 of their peers.
When students were again presented with photographs of pa-
tients, although the scores of both the control and intervention
groups improved, the gains were greater in the intervention group.
Not to be left behind by its Ivy League colleagues, Harvard’s
contribution to the field of art observation therapy involved trips to
the Boston Museum of Fine Arts by dermatology residents for
Visual Thinking Strategies that resulted in an improvement of their
observational skills.4 Clearly, there is merit to these approaches,
and the possibility of extending them to ophthalmology residents,
and even seasoned clinicians such as us, who could always
benefit from a reboot of their powers of observation.
Congratulations to the authors and editorialist for bringing this
work into the ophthalmologic realm.
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development in infants treated
with bevacizumab or laser
photocoagulation for retinopathy
of prematurity
(Ophthalmology. 2018;125:444-452)TO THE EDITOR: We read with interest the article by Vogel et al1
demonstrating the foveal development in infants treated with
bevacizumab or laser photocoagulation for retinopathy of
prematurity (ROP).1 The authors concluded that intravitreal
bevacizumab injection for ROP yields a more rapid outer retinal
thickening at the foveal center and laser photocoagulation is
related to delayed development of the ellipsoid zone at the
fovea.1 They also reported that the cystoid macular changes
observed in the patients were not associated with the
bevacizumab or laser treatment.1
When evaluating the effects of ROP treatment modalities on
foveal structures, it is beneficial to take into consideration several
confounding factors such as feeding pattern of the patient, birth
week, weight gain, initial weight, amount of oxygen use, envi-
ronmental lighting status, and associated systemic diseases. In
addition, there may be other, treatment-related factors that can
affect foveal structure, such as the intensity and extent of laser
treatment, as well as the dosing and number of bevacizumab
injections.
The study by Vogel et al1 might be improved by adding
some other macular imaging tests. OCT angiography would
provide valuable data about the vascular development of the
macula and status of the foveal avascular zone. In addition,
fundus fluorescein angiography should be performed in patients
with ROP, because the main pathology is associated with the
retinal vasculature. As the authors pointed out, long-term
follow-up is needed to better evaluate the effects of both treat-
ment modalities. In cases of ROP, it is difficult to determine if
having rapid outer retinal thickening is advantageous or delayed
development of the ellipsoid zone at the foveal center is disad-
vantageous, because the normal macular development patterns
may be somewhat altered. In further studies, performing vision
tests, including assessment of acuity, contrast sensitivity, color
vision, visual field, and a macula photo-stress test may provide
additional information about the physiological benefit of those
treatment options.
CorrespondenceThe beneficial effects of intravitreal anti-vascular endothelial
growth factor agents in ROP treatment have been demonstrated.2-4
There are some possible advantages of bevacizumab injection over
laser therapy. Bevacizumab treatment is superior, especially in
cases of aggressive posterior ROP and zone 1 disease.3,4 In contrast,
late-term recurrence rate and risk of persistent avascular zones may
be lower in laser treatment.5 Also, bevacizumab may have a risk of
deterioration of other organ systems because it passes into the
systemic circulation.3-5 In further studies, by taking into consider-
ation the miscellaneous confounding factors related to ROP, it
would be easier to draw conclusions about the effects of anti-
vascular endothelial growth factor and laser treatments on foveal
development.
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764e772.REPLY: We thank Drs Pekel and Pekel for their interest and
valuable commentary on our article. Our paper examines
the different effect that 2 common treatment options for
retinopathy of prematurity (ROP; laser photocoagulation and
intravitreal bevacizumab) have on foveal development.
The commenting authors raise important points on confounding
factors in these patients, including the feeding pattern of the patient,birth weight, weight gain, gestational age, amount of oxygen use,
environmental lighting status, and associated systemic diseases.
Several of these factors, such as age at birth and birth weight, were
adjusted for in our statistical models. Nevertheless, large prospec-
tive randomized studies would be needed to thoroughly control for
the wide range of possible confounders between treatment groups.
Further complicating this issue, some of these factors are also likely
important in the development of ROP (not just response to treat-
ment). Regarding the treatment-related factors, our patients treated
with bevacizumab received a single intravitreal injection with the
same dose for all patients. The same surgeon performed all the laser
treatments with similar power (although the extent of laser treat-
ment depended on the amount of avascular retina). Although these
factors may be useful within each treated group, the bevacizumab
group had more avascular retina than the laser group because of the
indications of treatment in each group. As the authors point out,
bevacizumab is superior in aggressive posterior ROP and zone 1
disease, and we use it in these cases.
We also agree that assessment of other anatomic features
associated with foveal development would be important to
examine. With regard to the foveal avascular zone, OCT angiog-
raphy is not yet available to us at the bedside and may not be
practical for imaging nonsedated infants in the near future owing to
motion artifact related to the lack of fixation. For the purposes of
this study, fluorescein angiography is not likely to add much
information on foveal development, because the resolution from
handheld imaging probes cannot adequately visualize the foveal
microvasculature.
As the authors point out, it is unknown whether rapid outer
retinal thickening is beneficial or detrimental. We agree it would be
of interest to follow these patients longitudinally to obtain more
clinical data to determine if either delayed or rapid development has
a clinical effect on visual function. Certainly, we encourage similar
parallel studies as the ROP demographics vary based on geography
and clinical setting.
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factors in syphilitic uveitis
(Ophthalmology. 2017;124:1808-1816)TO THE EDITOR: We read with interest the study by Hoogewoud
et al.1 The authors conducted a retrospective multicenter analysise57
